BioCryst Pharmaceuticals, Inc. (BCRX)

Market Cap	1.64B
Revenue (ttm)	412.58M
Net Income (ttm)	-123.82M
Shares Out	207.13M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,760,233
Open	7.86
Previous Close	7.87
Day's Range	7.82 - 8.04
52-Week Range	4.03 - 8.88
Beta	1.76
Analysts	Buy
Price Target	15.50 (+96.2%)
Earnings Date	Feb 24, 2025

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 1994
• Employees: 536
• Stock Exchange: NASDAQ
• Ticker Symbol: BCRX
• Website: https://www.biocryst.com

Financial Performance

In 2023, BioCryst Pharmaceuticals's revenue was $331.41 million, an increase of 22.37% compared to the previous year's $270.83 million. Losses were -$226.54 million, -8.33% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 96.20% from the latest price.

Price Target

$15.5

(96.20% upside)

Analyst Consensus: Buy